CD19 and acute lymphoblastic leukemia: In the treatment of hematological tumors, specifically targeted CAR macrophages (CAR-Ms) can produce superior antitumor effects against CD19-positive ALL cancer cells and HER2-positive human chronic myeloid leukemia passage cells (154).